SEARCH

SEARCH BY CITATION

References

  • 1
    Lawes DA, Sengupta SB, Boulos PB. Pathogenesis and clinical management of hereditary non-polyposis colorectal cancer. Br J Surg 2002; 89: 135769.
  • 2
    Lu K. Endometrial cancer in women with HNPCC. Int J Gynecol Cancer 2005; 15: 4001.
  • 3
    Liu T, Yan H, Kuismanen S, Percesepe A, Bisgaard M-L, Pedroni M, Benatti P, Kinzler KW, Vogelstein B, Ponz de Leon M, Peltomaki P, Lindblom A. The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. Cancer Res 2001; 61: 7798802.
  • 4
    Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 102738.
  • 5
    Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 25861.
  • 6
    Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997; 113: 114658.
  • 7
    Peltomaki, P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001; 10: 73540.
  • 8
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 91932.
  • 9
    Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21: 11749.
  • 10
    Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004; 10: 58459.
  • 11
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 32331.
  • 12
    Sager R. Tumor suppressor genes: the puzzle and the promise. Science 1989; 246: 140612.
  • 13
    Xu H, el-Gewely MR. P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol Annu Rev 2001; 7: 13164.
  • 14
    Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 4953.
  • 15
    Meek DW. The p53 response to DNA damage. DNA Repair (Amst) 2004; 3: 104956.
  • 16
    Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987; 7: 9613.
  • 17
    Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092100.
  • 18
    Dumont P, Leu JI, Della Pietra AC,III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 35765.
  • 19
    Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108: 1969.
  • 20
    Bonafe M, Salvioli S, Barbi C, Trapassi C, Tocco F, Storci G, Invidia L, Vannini I, Rossi M, Marzi E, Mishto M, Capri M, et al. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ 2004; 11: 96273.
  • 21
    Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 22934.
  • 22
    Bereir RE, Mohamed HS, Seielstad M, El Hassan AM, Khalil EAG, Peacock CS, Blackwell JM, Ibrahim ME. Allele frequency and genotype distribution of polymorphisms within disease-related genes is influenced by ethnic population sub-structuring in Sudan. Genetica 2003; 119: 5763.
  • 23
    Pegoraro RJ, Rom L, Lanning PA, Moodley M, Naiker S, Moodley J. P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer 2002; 12: 3838.
  • 24
    Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 26670.
  • 25
    Inserra P, Abrahamsen M, Papenfuss M, Giuliano AR. Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int J STD AIDS 2003; 14: 8004.
  • 26
    Arbel-Alon S, Menczer J, Feldman N, Glezerman M, Yeremin L, Friedman E. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. Int J Gynecol Cancer 2002; 12: 7414.
  • 27
    Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, Chakraborty R, Rothhammer F. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003; 36: 27983.
  • 28
    Giannoudis A, Graham DA, Southern SA, Herrington CS. p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer 1999; 83: 669.
  • 29
    Gustafsson AC, Guo Z, Hu X, Ahmadian A, Brodin B, Nilson A, Ponten J, Ponten F, Lundeberg J. HPV-related cancer susceptibility and p53 codon 72 polymorphism. Acta Derm Venereol 2001; 81: 1259.
  • 30
    Hayes VM, Hofstra R, Buys C, Hollema H, van der Zee AGJ. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet 1998; 352: 1756.
  • 31
    Helland A, Langerød A, Johnsen H, Olsen AO, Skovlund E, Børresen-Dale A-L. p53 polymorphism and risk of cervical cancer. Nature 1998; 396: 5301; author reply532.
  • 32
    Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF,Jr, Herrero R, Concepcion Bratti M, Schwartz P, Mortel R, Barnes W, Greenberg M, McGowan L, Scott DR, et al. p53 polymorphism and risk of cervical cancer. Nature 1998; 396: 5312.
  • 33
    Josefsson AM, Magnusson P, Ylitalo N, Quarforth-Tubbin Q, Ponten J, Adami HO, Gyllensten UB. p53 polymorphism and risk of cervical cancer. Nature 1998; 396: 531; author reply532.
  • 34
    Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res 1998; 58: 45856.
  • 35
    Nishikawa A, Fujimoto J, Akutagawa N, Iwasaki M, Takeuchi M, Fujinaga K, Kudo R. p53 Polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer. Int J Gynecol Cancer 2000; 10: 4027.
  • 36
    Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998; 352: 8712.
  • 37
    Settheetham-Ishida W, Singto Y, Yuenyao P, Tassaneeyakul W, Kanjanavirojkul N, Ishida T. Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in Northeastern Thailand. Cancer Lett 2004; 210: 20511.
  • 38
    Tenti P, Vesentini N, Rondo Spaudo M, Zappotore R, Migliora P, Carnevali L, Ranzani GN. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev 2000; 9: 4358.
  • 39
    Cortezzi SS, Provazzi PJ, Sobrinho JS, Mann-Prado JC, Pizzo Reis PM, Nobre de Freitas SE, Filho JFG, Fukuyama EE, Cordeiro JA, Cury PM, Maniglia JV, Villa LL, et al. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet Cytogenet 2004; 150: 449.
  • 40
    Hamel N, Black MJ, Ghadirian P, Foulkes WD. No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 2000; 82: 7579.
  • 41
    Scheckenbach K, Lieven O, Gotte K, Bockmuhl U, Zotz R, Bier H, Balz V. p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 2004; 13(11 Pt 1): 18059.
  • 42
    Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004; 89: 8689.
  • 43
    Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999; 5: 12934.
  • 44
    Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 2005; 11: 25029.
  • 45
    Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E. The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 2005; 92: 11448.
  • 46
    Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000; 3: 38992.
  • 47
    Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002; 179: 17583.
  • 48
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
  • 49
    Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, de la Chapelle A. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129: 41521.
  • 50
    Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Mohr J, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110: 10207.
  • 51
    Gaspari L, Pedotti P, Bonafe M, Franceschi C, Marinelli D, Mari D, Garte S, Taioli E. Metabolic gene polymorphisms and p53 mutations in healthy centenarians and younger controls. Biomarkers 2003; 8: 5228.
  • 52
    Fan R, Wu M-T, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9: 103742.
  • 53
    Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999; 354: 2189.
  • 54
    Zhang ZW, Newcomb P, Hollowood A, Feakins R, Moorghen M, Storey A, Farhing MJG, Alderson D, Holly J. Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003; 9: 21516.
  • 55
    Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591602.